Last reviewed · How we verify
VEGF Trap-Eye (BAY86-5321)
VEGF Trap-Eye (BAY86-5321) is a VEGF inhibitor / Soluble decoy receptor Biologic drug developed by Bayer. It is currently in Phase 3 development for Wet age-related macular degeneration (AMD), Diabetic macular edema (DME), Retinal vein occlusion (RVO).
VEGF Trap-Eye is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) to inhibit abnormal blood vessel growth in the eye.
VEGF Trap-Eye is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) to inhibit abnormal blood vessel growth in the eye. Used for Wet age-related macular degeneration (AMD), Diabetic macular edema (DME), Retinal vein occlusion (RVO).
At a glance
| Generic name | VEGF Trap-Eye (BAY86-5321) |
|---|---|
| Sponsor | Bayer |
| Drug class | VEGF inhibitor / Soluble decoy receptor |
| Target | VEGF (vascular endothelial growth factor) |
| Modality | Biologic |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
VEGF Trap-Eye functions as a fusion protein combining VEGF-binding domains from VEGF receptors with the Fc portion of human immunoglobulin. It acts as a molecular 'trap' that sequesters circulating VEGF and VEGF-B, preventing their interaction with endogenous VEGF receptors on endothelial cells. This blocks the pathological neovascularization and vascular permeability that characterize wet age-related macular degeneration and other retinal diseases.
Approved indications
- Wet age-related macular degeneration (AMD)
- Diabetic macular edema (DME)
- Retinal vein occlusion (RVO)
Common side effects
- Conjunctival hemorrhage
- Eye pain
- Floaters
- Intraocular inflammation
- Endophthalmitis
Key clinical trials
- The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema
- A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels Grow Abnormally in the Retina (Retinopathy of Prematurity)
- A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) (PHASE3)
- A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema (PHASE4)
- Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye (PHASE3)
- Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease (PHASE2, PHASE3)
- High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy (PHASE4)
- Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VEGF Trap-Eye (BAY86-5321) CI brief — competitive landscape report
- VEGF Trap-Eye (BAY86-5321) updates RSS · CI watch RSS
- Bayer portfolio CI
Frequently asked questions about VEGF Trap-Eye (BAY86-5321)
What is VEGF Trap-Eye (BAY86-5321)?
How does VEGF Trap-Eye (BAY86-5321) work?
What is VEGF Trap-Eye (BAY86-5321) used for?
Who makes VEGF Trap-Eye (BAY86-5321)?
What drug class is VEGF Trap-Eye (BAY86-5321) in?
What development phase is VEGF Trap-Eye (BAY86-5321) in?
What are the side effects of VEGF Trap-Eye (BAY86-5321)?
What does VEGF Trap-Eye (BAY86-5321) target?
Related
- Drug class: All VEGF inhibitor / Soluble decoy receptor drugs
- Target: All drugs targeting VEGF (vascular endothelial growth factor)
- Manufacturer: Bayer — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Wet age-related macular degeneration (AMD)
- Indication: Drugs for Diabetic macular edema (DME)
- Indication: Drugs for Retinal vein occlusion (RVO)